ArticleFrontiers in immunology2026
Identification and validation of prognostic genes related to glycolysis and M2 macrophage in hepatocellular carcinoma: an integrated analysis of bulk RNA sequencing and single-cell RNA sequencing.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The role of the crosstalk between glycolysis and M2 macrophages in hepatocellular carcinoma (HCC) progression remains incompletely understood. This study aimed to identify prognostic genes linked to both glycolysis and M2 macrophages in HCC and to elucidate their mechanistic underpinnings. Methods: Single-cell RNA sequencing (scRNA-seq) and transcriptomic data (TCGA-LIHC) were obtained from public databases. M2 macrophage-related genes (MRGs) were integrated with differentially expressed genes (DEGs1) from immune infiltration analysis and macrophage polarization-related genes (MPRGs). Candidate genes were identified through the intersection of glycolysis-related genes (GRGs), MRGs, and HCC-control DEGs (DEGs2). Prognostic genes were selected Results: Fifty-two candidate genes were identified from the intersection of GRGs, MRGs, and DEGs2. Eight genes-PFKFB4, ADH4, ADH1C, ME1, FOXK1, PFKP, ARL2, and TKTL1-were selected as prognostic genes. ADH4 and ADH1C exhibited significantly higher expression in the low-risk group, whereas the other genes were elevated in the high-risk group. A more accurate risk model and nomogram were developed. Further analyses indicated that the prognostic genes might contribute to HCC progression through pathways such as drug metabolism (cytochrome P450), immune cell infiltration (naive B cells and M2 macrophages), immune escape, and drug sensitivity (e.g., A.770041), potentially influencing cellular interactions and differentiation states of hepatocytes and M2 macrophages. RT-qPCR confirmed that PFKFB4, FOXK1, and TKTL1 were upregulated in HCC, while ADH4 and ADH1C were downregulated. Conclusion: Eight prognostic genes were identified, and a risk model was established, providing valuable insights for clinical prognostic prediction and immunotherapy in HCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.